drugset / Trial / NCT03566199
MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
Phase 1/2
Completed
7 enrolled
Sabine Mueller, MD, PhD
Midatech Pharma US Inc. · collabPacific Pediatric Neuro-Oncology Consortium · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II trial studies the side effects of panobinostat nanoparticle formulation MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine glioma. Panobinostat nanoparticle formulation MTX110 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2018-05-22
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | — | Other |